Development of a novel therapeutic vaccine carrier that sustains high antibody titers against several targets simultaneously

Autor: Per-Olof Markgren, Lars Hellman, U. Helena Danielson, C. Evalena Andersson, Anna-Karin Olsson, Julia Femel, Falk Saupe, Sebastian Deindl, Elisabeth J. M. Huijbers, Matthias Reichel

Publikováno v: Saupe, F, Reichel, M, Huijbers, E J M, Femel, J, Markgren, P-O, Andersson, C E, Deindl, S, Danielson, U H, Hellman, L T & Olsson, A-K 2017, ' Development of a novel therapeutic vaccine carrier that sustains high antibody titers against several targets simultaneously ', FASEB Journal, vol. 31, no. 3, pp. 1204-1214 . https://doi.org/10.1096/fj.201600820R
FASEB Journal, 31(3), 1204-1214. FASEB

With the aim to improve the efficacy of therapeutic vaccines that target self-antigens, we have developed a novel fusion protein vaccine on the basis of the C-terminal multimerizing end of the variable lymphocyte receptor B (VLRB), the Ig equivalent

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9e4864bd13e52741c1b2f80dedc1a65
https://doi.org/10.1096/fj.201600820r

Elucidation of HIV-1 protease resistance by characterization of interaction kinetics between inhibitors and enzyme variants

Autor: Markku Hämäläinen, Cynthia F. Shuman, Per Olof Markgren, U. Helena Danielson

Publikováno v: Antiviral Research. 58:235-242

The kinetics of the interaction between drug-resistant variants of HIV-1 protease (G48V, V82A, L90M, I84V/L90M, and G48V/V82A/I84V/L90M) and clinically used inhibitors (amprenavir, indinavir, nelfinavir, ritonavir, and saquinavir) were determined usi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02218f8607b4960e56a43d92e32052ab
https://doi.org/10.1016/s0166-3542(03)00002-0

P1/P1′ modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays

Autor: Hans Sjöbom, Johan Hultén, Stefan Löfås, Markku Hämäläinen, Mathias Alterman, Björn Classon, Bertil Samuelsson, U. Helena Danielson, Anders Hallberg, Pär Säfsten, Per-Olof Markgren

Publikováno v: European Journal of Pharmaceutical Sciences. 13:203-212

The commonly used HIV-1 protease assays rely on measurements of the effect of inhibitions on the hydrolysis rate of synthetic peptides. Recently an assay based on surface plasmon resonance (SPR) was introduced. We have taken advantage of the fact tha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6697fc7c4ae6511629e999199f1aae6
https://doi.org/10.1016/s0928-0987(01)00109-9

Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs

Autor: Per-Olof Markgren, Ulrika Nillroth, Anders Hallberg, Johan Hultén, Lotta Vrang, U H Danielson

Publikováno v: Antimicrobial Agents and Chemotherapy. 41:2383-2388

Resistant virus was isolated from virus propagated in cell culture in the presence of the human immunodeficiency virus type 1 (HIV-1) proteinase inhibitor DMP 323, Ro 31-8959, or A-75925. The proteinase gene of resistant virus was sequenced, and key

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::452800d3e5c74c25d85eb2a017ee8b80
https://doi.org/10.1128/aac.41.11.2383

Determination of interaction kinetic constants for HIV-1 protease inhibitors using optical biosensor technology

Autor: Per-Olof Markgren, Markku Hämäläinen, Robert Karlsson, U. Helena Danielson, Karl Gertow, Maria T. Lindgren

Publikováno v: Analytical biochemistry. 291(2)

The interaction between HIV-1 protease and inhibitors has been studied with optical biosensor technology. Optimized experimental procedures and mathematical analysis permitted determination of association and dissociation rate constants. A sensor sur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90d0cb4074b63635dd3399a52298113f
https://pubmed.ncbi.nlm.nih.gov/11401294